In Situ Gene Therapy via AAV-CRISPR-Cas9-Mediated Targeted Gene Regulation

Copyright © 2018 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.

Bibliographic Details
Published in:Molecular therapy : the journal of the American Society of Gene Therapy, Vol. 26, No. 7 (2018), p. 1818-1827
Main Author: Moreno, Ana M
Other Involved Persons: Fu, Xin ; Zhu, Jie ; Katrekar, Dhruva ; Shih, Yu-Ru V ; Marlett, John ; Cabotaje, Jessica ; Tat, Jasmine ; Naughton, John ; Lisowski, Leszek ; Varghese, Shyni ; Zhang, Kang ; Mali, Prashant
Format: electronic Article
Language:English
ISSN:1525-0024
Item Description:Date Completed 26.06.2019
Date Revised 05.07.2019
published: Print-Electronic
Citation Status MEDLINE
Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Physical Description:Online-Ressource
DOI:10.1016/j.ymthe.2018.04.017
Subjects:
QR Code: Show QR Code
LEADER 04546nma a2200865 c 4500
001 NLM284335940
003 DE-601
005 20190714071820.0
007 cr uuu---uuuuu
008 180527s2018 000 0 eng d
024 7 |a 10.1016/j.ymthe.2018.04.017  |2 doi 
028 5 2 |a pubmed19n1292.xml 
035 |a S1525-0016(18)30174-6 
035 |a (DE-599)NLM29754775 
040 |b ger  |c GBVCP 
041 0 |a eng 
100 1 |a Moreno, Ana M 
245 1 0 |a In Situ Gene Therapy via AAV-CRISPR-Cas9-Mediated Targeted Gene Regulation  |h Elektronische Ressource 
300 |a Online-Ressource 
500 |a Date Completed 26.06.2019 
500 |a Date Revised 05.07.2019 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
500 |a Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine 
520 |a Copyright © 2018 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved. 
520 |a Development of efficacious in vivo delivery platforms for CRISPR-Cas9-based epigenome engineering will be critical to enable the ability to target human diseases without permanent modification of the genome. Toward this, we utilized split-Cas9 systems to develop a modular adeno-associated viral (AAV) vector platform for CRISPR-Cas9 delivery to enable the full spectrum of targeted in situ gene regulation functionalities, demonstrating robust transcriptional repression (up to 80%) and activation (up to 6-fold) of target genes in cell culture and mice. We also applied our platform for targeted in vivo gene-repression-mediated gene therapy for retinitis pigmentosa. Specifically, we engineered targeted repression of Nrl, a master regulator of rod photoreceptor determination, and demonstrated Nrl knockdown mediates in situ reprogramming of rod cells into cone-like cells that are resistant to retinitis pigmentosa-specific mutations, with concomitant prevention of secondary cone loss. Furthermore, we benchmarked our results from Nrl knockdown with those from in vivo Nrl knockout via gene editing. Taken together, our AAV-CRISPR-Cas9 platform for in vivo epigenome engineering enables a robust approach to target disease in a genomically scarless and potentially reversible manner 
611 2 7 |a Journal Article  |2 gnd 
611 2 7 |a Research Support, N.I.H., Extramural  |2 gnd 
611 2 7 |a Research Support, Non-U.S. Gov't  |2 gnd 
653 2 |a Animals  |6 D000818 
653 2 |a CRISPR-Cas Systems  |6 D064113  |a *genetics  |6 Q000235 
653 2 |a Cell Line  |6 D002460 
653 2 |a Clustered Regularly Interspaced Short Palindromic Repeats  |6 D064112  |a *genetics  |6 Q000235 
653 2 |a Dependovirus  |6 D000229  |a *genetics  |6 Q000235 
653 2 |a Gene Editing  |6 D000072669  |a methods  |6 Q000379 
653 2 |a Gene Expression Regulation  |6 D005786  |a *genetics  |6 Q000235 
653 2 |a Genetic Engineering  |6 D005818  |a methods  |6 Q000379 
653 2 |a Genetic Therapy  |6 D015316  |a methods  |6 Q000379 
653 2 |a Genetic Vectors  |6 D005822  |a genetics  |6 Q000235 
653 2 |a HEK293 Cells  |6 D057809 
653 2 |a Humans  |6 D006801 
653 2 |a Mice  |6 D051379 
653 2 |a Mice, Inbred C57BL  |6 D008810 
653 2 |a Retinal Cone Photoreceptor Cells  |6 D017949  |a physiology  |6 Q000502 
653 2 |a Retinal Rod Photoreceptor Cells  |6 D017948  |a physiology  |6 Q000502 
653 2 |a Retinitis Pigmentosa  |6 D012174  |a genetics  |6 Q000235 
653 2 |a Transcription, Genetic  |6 D014158  |a genetics  |6 Q000235 
655 7 |a CRISPR-Cas9  |2 gnd 
655 7 |a gene therapy  |2 gnd 
655 7 |a retinitis pigmentosa  |2 gnd 
689 0 0 |A f  |a Journal Article 
689 0 1 |A f  |a Research Support, N.I.H., Extramural 
689 0 2 |A f  |a Research Support, Non-U.S. Gov't 
689 0 |5 DE-601 
689 1 0 |a CRISPR-Cas9 
689 1 1 |a gene therapy 
689 1 2 |a retinitis pigmentosa 
689 1 |5 DE-601 
700 1 |a Fu, Xin 
700 1 |a Zhu, Jie 
700 1 |a Katrekar, Dhruva 
700 1 |a Shih, Yu-Ru V 
700 1 |a Marlett, John 
700 1 |a Cabotaje, Jessica 
700 1 |a Tat, Jasmine 
700 1 |a Naughton, John 
700 1 |a Lisowski, Leszek 
700 1 |a Varghese, Shyni 
700 1 |a Zhang, Kang 
700 1 |a Mali, Prashant 
773 0 8 |i in  |t Molecular therapy : the journal of the American Society of Gene Therapy  |g Vol. 26, No. 7 (2018), p. 1818-1827  |q 26:7<1818-1827  |w (DE-601)NLM10824234X  |x 1525-0024 
856 4 1 |u http://dx.doi.org/10.1016/j.ymthe.2018.04.017  |3 Volltext 
912 |a GBV_NLM 
951 |a AR 
952 |d 26  |j 2018  |e 7  |c 00  |h 1818-1827